Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors.
Our lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. We believe that our preliminary Phase 1/2 data from our ongoing clinical trial provide us with clinical proof of concept for our HER2 Boltbody ISAC approach.
Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1.
December 6, 2021
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021 Read More
December 2, 2021
Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021Read More
November 19, 2021
Bolt Biotherapeutics Announces Changes to its Board of DirectorsRead More
December 6, 2021 at 8:00 AM EST
Bolt Biotherapeutics Webcast at ESMO IO Congress 2021 Read More
November 16, 2021 at 4:00 PM EST
Stifel 2021 Virtual Healthcare Conference Read More
November 12, 2021
2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting Read More